GB Sciences (GBLX) Stock Price, News & Analysis

Company Overview

GB Sciences, Inc. is a biotechnology company focused on the research, development and commercialization of cannabinoid-based medicines. Leveraging both botanical and synthetic approaches, the company aims to create novel therapies targeting oncology, neurology and inflammatory diseases. Through its proprietary drug discovery platform, GB Sciences seeks to identify and advance lead compounds that harness the therapeutic potential of cannabinoids while ensuring high standards of quality and safety.

The company operates a cGMP-compliant research and manufacturing facility in Irvine, California, and maintains partnerships to support cultivation and extraction activities in select geographies. GB Sciences has secured licenses for cannabis cultivation and product manufacturing in Panama, positioning the company to serve markets across North and Central America. Its product pipeline includes preclinical and early-stage clinical candidates, as well as formulations designed for future human trials in key therapeutic areas.

GB Sciences’ leadership team combines expertise in pharmaceutical development, botanical extraction and regulatory compliance. The company is led by President and Chief Executive Officer Dr. Federico Narváez, MD, whose background spans clinical research and drug development. Supported by scientific and operational executives, GB Sciences continues to pursue strategic collaborations and patent-protected innovations aimed at translating cannabinoid science into meaningful medical treatments.

Key Stats

• Today's Range: $0.0002 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0085
• Volume: 1.03 million shs
• Average Volume: 85,820 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GBLX Stock Analysis - Frequently Asked Questions

How have GBLX shares performed this year?

GB Sciences' stock was trading at $0.0040 at the beginning of the year. Since then, GBLX shares have decreased by 92.5% and is now trading at $0.0003.

How were GB Sciences' earnings last quarter?

GB Sciences, Inc. (OTCMKTS:GBLX) announced its earnings results on Monday, November, 14th. The company reported ($0.04) EPS for the quarter.

How do I buy shares of GB Sciences?

Shares of GBLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GB Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GB Sciences investors own include Canopy Growth (CGC), 22nd Century Group (XXII), NVIDIA (NVDA), Unrivaled Brands (TRTC), TREES (CANN), Aurora Cannabis (ACB) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/14/2016
• Today: 10/21/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:GBLX
• CIK: 1165320
• Web: gbsciences.com
• Phone: (866) 721-0297
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A